Global rank-invariant set normalization (GRSN) to reduce systematic distortions in microarray data by Pelz, Carl R et al.
BioMed  Central
Page 1 of 18
(page number not for citation purposes)
BMC Bioinformatics
Open Access Methodology article
Global rank-invariant set normalization (GRSN) to reduce 
systematic distortions in microarray data
Carl R Pelz1, Molly Kulesz-Martin2,3,5, Grover Bagby1,4,5 and 
Rosalie C Sears*1,5
Address: 1Department of Molecular and Medical Genetics, Oregon Health and Sciences University, Portland, OR 97239-3098, USA, 2Department 
of Dermatology, Oregon Health and Sciences University, Portland, OR 97239-3098, USA, 3Department of Cell and Developmental Biology, 
Oregon Health and Sciences University, Portland, OR 97239-3098, USA, 4Department of Medicine, Oregon Health and Sciences University, 
Portland, OR 97239-3098, USA and 5OHSU Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR 97239-3098, USA
Email: Carl R Pelz - pelzc@ohsu.edu; Molly Kulesz-Martin - kuleszma@ohsu.edu; Grover Bagby - grover@ohsu.edu; 
Rosalie C Sears* - searsr@ohsu.edu
* Corresponding author    
Abstract
Background:  Microarray technology has become very popular for globally evaluating gene
expression in biological samples. However, non-linear variation associated with the technology can
make data interpretation unreliable. Therefore, methods to correct this kind of technical variation
are critical. Here we consider a method to reduce this type of variation applied after three common
procedures for processing microarray data: MAS 5.0, RMA, and dChip®.
Results: We commonly observe intensity-dependent technical variation between samples in a
single microarray experiment. This is most common when MAS 5.0 is used to process probe level
data, but we also see this type of technical variation with RMA and dChip® processed data. Datasets
with unbalanced numbers of up and down regulated genes seem to be particularly susceptible to
this type of intensity-dependent technical variation. Unbalanced gene regulation is common when
studying cancer samples or genetically manipulated animal models and preservation of this
biologically relevant information, while removing technical variation has not been well addressed in
the literature. We propose a method based on using rank-invariant, endogenous transcripts as
reference points for normalization (GRSN). While the use of rank-invariant transcripts has been
described previously, we have added to this concept by the creation of a global rank-invariant set
of transcripts used to generate a robust average reference that is used to normalize all samples
within a dataset. The global rank-invariant set is selected in an iterative manner so as to preserve
unbalanced gene expression. Moreover, our method works well as an overlay that can be applied
to data already processed with other probe set summary methods. We demonstrate that this
additional normalization step at the "probe set level" effectively corrects a specific type of technical
variation that often distorts samples in datasets.
Conclusion: We have developed a simple post-processing tool to help detect and correct non-
linear technical variation in microarray data and demonstrate how it can reduce technical variation
and improve the results of downstream statistical gene selection and pathway identification
methods.
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Background
Given the large volume of data generated by microarray
technology and the many sources of variation involved,
including not only biologically relevant variation, but
also technical variation that results from sample prepara-
tion and labeling, hybridization, and other processing
steps [1], methods for analyzing and interpreting the
results are very important. An important component of
these technologies is redundancy. For example, the Affi-
ymetrix®  GeneChip®  platform, employs many features
(probes) to interrogate each gene (transcript). These
redundant probes are called a "probe set" and summariz-
ing each probe set to arrive at a robust value representing
the abundance of the associated transcript is one of the
first steps in any analysis [2]. Another important step is
normalization to remove systematic array to array varia-
tion such as differential hybridization and scanning arti-
facts. Some popular processing methods for these steps
are the MAS 5.0 algorithm [3] developed by Affymetrix®,
the Robust Multichip Average (RMA) method developed
by Irizarry et al. [2], and the dChip® method developed by
Li et al. [4]. Each of these include normalization methods:
MAS 5.0 uses a simple global scaling factor [3], RMA uses
quantile normalization [5], and dChip®  http://
www.dchip.org uses a rank-invariant set based method
[4]. By definition, the global scaling method of MAS 5.0
cannot handle non-linear artifacts. Furthermore, it may
not even produce the optimal linear scaling factor as sug-
gested by Lu [6]. Still, the MAS 5.0 method is commonly
used and even preferred by some researchers for some
applications [7]. RMA has a number of advantages over
MAS 5.0 including quantile normalization, which is a
mathematically elegant solution for setting the intensity
distributions equal for all arrays in the dataset [2,5,8].
However this is not always appropriate and may cause
problems when the assumption of equal distributions is
not met, for example when more probe sets are up-regu-
lated than down-regulated as discussed by Freudenberg et
al. [9]. dChip® uses a rank-invariant set based normaliza-
tion method on probe level data, however the dChip®
approach selects one reference sample and compares all
other samples to it, selecting a different rank-invariant set
to normalize each sample. Using our proposed method
based on a global rank-invariant set to create a robust
average reference, which we refer to as Global Rank-invar-
iant Set Normalization (GRSN) and applying it to the
summarized probe set data from dChip®, we see a further
reduction in specific types of systematic array to array var-
iation.
For the purpose of this discussion, we will classify the var-
iation of microarray data into three categories: biological,
random, and systematic. Biological variation is of interest
to the researcher and may contain many different compo-
nents. The random and systematic categories are both
forms of technical variation. Random variation has no
biological relevance and is the result of uncharacterizable
measurement errors. Systematic variation also has no bio-
logical relevance, but is characterizable as a function of
expression value. We are interested in systematic variation
because it can be "modeled" and removed. For example,
if any of the microarray processing steps (labeling, hybrid-
ization, scanning, etc.) are non-linear functions of tran-
script abundance, and the conditions affecting these non-
linear functions change from array to array or with bio-
logic condition due to unbalanced gene expression, then
systematic variation will be introduced between arrays
and/or conditions. The goal of this work is to graphically
show and mathematically remove this type of variation,
which we refer to as "non-linear artifacts" or "skew". We
use rank-invariant transcripts as reference points to detect
and remove these non-linear artifacts. This is not a new
concept, for example, Li and Wong [4] use rank-invariant
probes for normalization in their dChip software. How-
ever, we have extended this idea by selecting a global set
of endogenous, rank-invariant, transcripts to generate
average reference points used to normalize all samples in
a dataset. We also apply our normalization as an addi-
tional step after using existing methods for summarizing
probe sets. The efficacy of additional normalization at the
"probe set level" has been advocated by others [10]. Using
a global rank-invariant set (as opposed to selecting a new
rank-invariant set for each sample) reduces the risk of
introducing noise into the dataset. Applying our method
as a post probe set summary method allows us the flexi-
bility of using our favorite probe set summary method. In
addition, the summarized probe set values should give the
best estimate of true gene expression, so it makes sense to
use these values when selecting the rank-invariant set.
With the use of optimized probe set definitions as
described by Sandberg and Larson [11], this may become
even more beneficial.
In our experience with microarray datasets, both from
human cancer studies and animal models, it is common
to have unbalanced up or down regulation of gene expres-
sion between two sample populations. When using the
standard data processing methods discussed above, we
often see an intensity-dependent skew when comparing
conditions in such data. This skew, in turn, introduces
errors in further statistical analysis and in the calculation
of fold change. These errors will bias the results of gene
selection based on statistics and fold change and can lead
to the detection of "statistically significant" genes that are
not in fact differentially expressed. GRSN is a simple, yet
robust, method for reducing this type of distortion, and
minimizing the chances of obtaining misleading analysis
results. We use simulated data to show that GRSN reliably
reduces non-linear skew even when actual gene expres-
sion is highly unbalanced. GRSN does not introduce biasBMC Bioinformatics 2008, 9:520 http://www.biomedcentral.com/1471-2105/9/520
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into the dataset by trying to balance the number or mag-
nitude of up and down regulated genes. As a result, GRSN
performs well on a wide range of datasets, including data-
sets with as few as two samples.
Results
Visualizing non-linear technical variation in microarray 
data
In microarray datasets, we expect only a small fraction of
the transcripts interrogated by an array to be differentially
expressed. Therefore, when utilizing a scatter plot to com-
pare pairs of samples, we expect to see most transcripts
centered along the diagonal line. When this is not the
case, further normalization may be required. We have
examined over 30 publicly available datasets, and found
many to contain samples with systematic non-linear dis-
tortions apparent in their scatter plots. In this report, we
will consider a variety of datasets demonstrating various
degrees of non-linear distortions, and the effect of GRSN
correction. An example of non-linear distortions between
microarray samples within a dataset is shown in Fig. 1A.
This graph compares two normal samples from a study of
the inherited disease, Fanconi Anemia (GB dataset) using
patient bone marrow samples run on the Affymetrix® HG-
U133A GeneChip®. There is a distinctive curve to the data
in the scatter plot (top left panel) when the MAS 5.0
method is used to process the data. This "frown" is even
more evident when the data is plotted using a standard M
vs. A plot (bottom left panel). The M vs. A plot [12] pro-
vides an optimal visualization of the ratio of two samples
as a function of expression level. In Fig. 1A, columns 2 and
3, although not as pronounced, we also see a systematic
skewing of the data when the RMA or dChip methods are
used to process this data (most apparent on the M vs. A
style plots). Similar distortions can be seen in other sam-
ples in this dataset and additional examples from this and
other datasets are shown in subsequent figures. We have
developed a method called Global Rank-invariant Set
Normalization (GRSN) in an effort to reduce this type of
non-linear technical variation.
Global Rank-invariant Set Normalization
GRSN is based on the general idea of rank-invariant genes
presented by Li and Wong [4]. We extend this idea to
select a single, globally rank-invariant set of endogenous
genes to be used to normalize all samples in a dataset.
These are genes believed to be consistently expressed in all
samples within a given dataset and should appear in
roughly the same rank order in each sample when sorted
by expression level. Importantly, this ordering, or rank,
should not be affected by the types of non-linear artifacts
that this normalization method is designed to correct.
An overview of the GRSN method is shown in Figure 1B.
Briefly, all transcripts (representing endogenous genes)
are ranked in each sample of a dataset based on expres-
sion (as calculated by summarizing probe sets using estab-
lished methods such as RMA or MAS 5.0). The variance of
the rank order for each transcript is then calculated across
all of the samples. Transcripts with the highest rank vari-
ance are discarded. The remaining transcripts are again
ranked and the process is repeated in an iterative fashion.
This iteration cycle is important because, for datasets with
unbalanced numbers of up and down regulated tran-
scripts, there can be a global shift of transcript rank order
caused by the most differentially regulated transcripts.
This global shift of the rank order will disappear as the
most differentially regulated transcripts (with the highest
rank variance) are discarded during the first few iteration
cycles. Note that if we require the global rank-invariant set
to have rank variance of zero for all transcripts, we will not
typically have enough transcripts for an effective calibra-
tion curve, i.e. the set of transcripts with exactly the same
rank order in all samples is too small. Therefore, the iter-
ation cycle is terminated when a reasonable number of
approximately rank-invariant transcripts remain (5000 by
default). These probe sets are considered the "Global
Rank-invariant Set" (GRiS).
A single virtual reference sample is then created by taking
the trimmed mean (mean after removing 25% of the val-
ues from the top and bottom of the range) expression
value (over the entire dataset) for each summarized probe
set (transcript), and M vs. A plots are generated comparing
each sample to this virtual reference. This provides a visu-
alization of the effect of applying GRSN. Fig. 2, column 1
shows the M vs. A plots comparing sample (N3) to the vir-
tual reference of the GB dataset after the data is summa-
rized using MAS 5.0 (first row), RMA (second row), or
dChip (last row). We then generate a M vs. A plot of the
identified GRiS transcripts only, comparing expression
values from a given sample to expression values from the
virtual reference sample (Fig. 2, column 2, blue points).
We use lowess [13] to fit a smooth curve through these
points (green line). This smoothed curve is used as the cal-
ibration curve for this sample. We then calculate an inten-
sity-dependent adjustment for transcripts in each sample
which, when applied, will center the sample's GRiS on the
horizontal line of the M vs. A plot (at M = 0). Fig. 2, col-
umn 2, also shows the GRiS after calibration of this sam-
ple (red dots). Fig. 2, column 3, then shows all transcripts
after calibration of the sample compared to the virtual ref-
erence sample (red dots). This process is repeated for each
sample, with a different calibration curve generated each
time (using the same GRiS). Using the trimmed mean val-
ues of the GRiS as the reference for normalization pro-
vides a robust average across all samples so that the
linearity of the normalized data is not affected by a few
samples with anomalous non-linear artifacts. Note that
these intensity-dependent adjustments are applied addi-BMC Bioinformatics 2008, 9:520 http://www.biomedcentral.com/1471-2105/9/520
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Visualization of typical non-linear artifacts in microarray data and the GRSN method used to reduce them Figure 1
Visualization of typical non-linear artifacts in microarray data and the GRSN method used to reduce them. A. 
Visualizing non-linear technical artifacts. Top row – standard log base 2 scatter plots comparing normal sample N3 to normal 
sample N5 from a clinical study of Fanconi Anemia, (GB dataset). Bottom row – the same data as in the top row, but plotted 
using M vs. A plots in which M is plotted as a function of A where M = log2(Y) – log2(X) and A = (log2(Y) + log2(X))/2 with X 
= expression values for sample 1 and Y = expression values for sample 2. The probe set summary methods used are (from left 
to right): MAS 5.0, RMA, and dChip®. B. A flow chart showing the basic steps followed by the GRSN algorithm to reduce the 
type of non-linear artifact shown in A.
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processing method such as:
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with rows representing
transcripts and columns
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Create a rank matrix of
the same dimension as
the data matrix and
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with the ranks of the
transcripts in that
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on expression value.
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each row (transcript) in
the rank matrix.
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highest rank variance
and also remove the cor-
responding rows from
the data matrix.
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ing 1/4 of the difference
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transcript count and the
selected numberof
approximate rank
invariant transcripts to
use each time.
The transcripts repre-
sented by the remaining
rows are the Global
Rank-invariant Set
(GRiS).
Use lowess to smooth the
calibration curve for
each sample.
Use the smoothed cali-
bration curve to apply
an intensity-dependent
adjustment to all tran-
scripts in the sample.
Repeat foreach sample.
Done
Foreach sample, create
a calibration curve by
comparing the GRiS
reference values to the
GRiS values forthat
sample.
Reference values for
each GRiS transcript are
calculated by taking the
t r i m m e dm e a na c r o s sa l l
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GRSN corrects non-linear distortions apparent in different summary methods Figure 2
GRSN corrects non-linear distortions apparent in different summary methods. M vs. A plots demonstrating the 
GRSN method applied to the MAS 5.0, RMA, and dChip® probe set summary methods. Column 1 shows M vs. A plots compar-
ing one selected sample to the virtual reference sample created by taking the trimmed mean expression value of each probe 
set in that dataset. Column 2 shows the global rank-invariant set (GRiS) of 5,000 probe sets before GRSN normalization in blue 
and after normalization in red (note change in y-axis scale). The smoothed curve through the rank-invariant set is shown in 
green. This is the calibration curve used to normalize the selected sample. Column 3 shows all probe sets after GRSN normal-
ization of the selected sample compared to the virtual reference sample. The sample shown is N3 from the GB dataset. The 
probe set summary methods used are (from top to bottom): MAS 5.0, RMA, and dChip®.
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tively to the log scaled data and that this is equivalent to
an intensity-dependent scaling of the original, non-log
scaled data.
Determining global rank-invariant set size
When selecting the GRiS, we aim to minimize the rank
order variation among transcripts in the set. We do not
attempt to select a set with no rank variation because this
would normally result in too few transcripts to define a
smooth calibration curve. Therefore, when choosing the
size of the global rank-invariant set, we must balance the
desire for rank-invariant transcripts with the need for a
sufficient number of calibration points. The effect of
selecting too few transcripts is demonstrated in Fig. 3A.
Here, multiple calibration curves (using different num-
bers of approximately global rank-invariant transcripts)
are graphed for a single sample. The five red curves repre-
sent calibration curves generated using GRiS sizes of 100,
200, 300, 400, and 500. At this size range, the curves are
erratic and segmented. The five green curves represent
sizes of 2000, 4000, 6000, 8000, and 10,000. At this size
range, the calibration curves smooth out and become
more consistent. We conclude that GRiS sizes in the range
of 100 to 500 are insufficient, but that sizes in the range
of 2000 to 10,000 appear to be adequate.
Next, we look at the effect of different GRiS sizes on the
detection of statistically significant genes. For each candi-
Selection of the global rank-invariant set size Figure 3
Selection of the global rank-invariant set size. A. The effect of selecting different sized Global Rank-invariant Sets (GRiS) 
on the calibration curves for a given sample. Each curve shows the GRSN calculated adjustment value as a function of expres-
sion value (for a given sample). Red curves are from GRiS sizes of 100, 200, 300, 400, and 500. Green curves are from GRiS 
sizes of 2000, 4000, 6000, 8000, and 10000. The blue curve is from the default GRiS size of 5000. GB dataset comparing Fan-
coni vs. Normal using MAS 5.0 processed data on left and RMA processed data on the right (notice different y-axis scales). B. 
The effect of changing the GRiS size on the selection of significantly regulated genes. Each bar represents the difference in the 
lists of significant genes found due to a change in the size of the GRiS. The red bar represents the default size of 5000 vs. none 
(not using GRSN) and is meant to show the magnitude of the effect of applying GRSN (a reference point for the other bars). 
The three blue bars represent, in order from left to right, the difference of 5000 to 10000, 10000 to 15000, and 15000 to 
20000. Top Row – GB dataset comparing Fanconi vs. Normal using MAS 5.0 processed data on left and RMA processed data 
on the right. On left, GSE6802 dataset comparing R vs. C, using RMA. On right, 339RS dataset comparing TA vs. C using RMA.
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date rank-invariant set size, we apply the GRSN method
followed by a statistical analysis to identify lists of up and
down regulated genes. We used the eBayes and topTable
functions from the limma [14] package in BioConductor
with a FC cutoff of 1.5 and a False Discovery Rate (FDR)
cutoff of 0.05 (5%) to select statistically significant genes.
The FDR method [15,16] applies to multiple hypothesis
testing. It uses calculated P-values to control the rate of
false positives expected from a set of statistical tests. To
compare two candidate sizes for the GRiS, we compare
these lists of genes. For the two up regulated lists, we
count the number of genes that are in one or the other list,
but not both. We do the same for the down regulated lists
and add the results. This gives us the number of genes
affected by the change in the rank-invariant set size. In Fig.
3B, we use a bar graph to report the numbers of affected
genes when different rank-invariant set sizes are com-
pared. As a reference point, we compare GRSN with a
GRiS size of 5,000 to no GRSN normalization (red bar).
This serves to quantify the effect of the GRSN method
itself. To quantify the "stability" at reasonably sized rank-
invariant sets, we compare 5 K to 10 K, 10 K to 15 K and
15 K to 20 K (blue bars). The effect of applying GRSN (red
bar) is large while the effect of changing the rank-invariant
set size above 5 K (blue bars) is small. In summary, the
size of the rank-invariant set does not seem to be critical.
Any value in the range of 5 K to 20 K should work equally
well on the current high-density arrays. However, given
that we want to minimize rank variance in our selected
GRiS, we use a default size of 5 K (5000) for high density
arrays with greater than 20,000 probe sets.
The choice of the smoother span supplied to the lowess
function (see Methods section) can also effect the calibra-
tion curves. We have evaluated a range of values for this
parameter (data not shown) and have chosen 0.25 as the
default for GRSN. However, in a few cases, this default
value may not be optimal. For example, some datasets
(such as the simulation study presented below) produce a
GRiS that is not evenly distributed along the full transcript
expression range. In these cases, a larger smoother span
may be needed to produce a smooth calibration curve. In
the case of the simulation study described below, we
chose 0.50 for the smoother span (see Fig. 4A). The trade-
off is that increasing the smoother span can lead to cali-
bration curves that do not properly track the GRiS at the
extreme ends of the transcript expression range. We rec-
ommend starting with the default value of 0.25, but
checking the calibration curves plotted by the GRSN
method for continuity with the GRiS (see Fig. 2, column
2).
GRSN improves statistical performance in simulated data
When evaluating the performance of GRSN on a given
microarray dataset, we are confronted with the typical
problem of not knowing a priori which transcripts are
truly regulated and by how much. Therefore, we have cre-
ated simulated datasets where we have artificially intro-
duced differential gene expression so that we do know a
priori which genes are regulated and to what degree. We
then introduce simulated, systematic, non-linear artifacts
(skew) typical of what are seen in real world datasets. This
data allows us to evaluate the ability of standard statistical
methods to identify the correct up and down regulated
genes before the simulated artifacts are introduced, after
they are introduced, and after applying GRSN to correct
the simulated artifacts. Thus, the performance of GRSN
can be evaluated with respect to reducing unwanted vari-
ance and improving statistical gene selection perform-
ance.
To create a relatively realistic simulated dataset, we used a
dataset from a cell culture model with 10 biological con-
trol replicates (run on Affymetrix®  HG-U133_Plus_2
GeneChips® and processed using the RMA method) to
obtain typical background variance (the non-linear arti-
facts for this dataset were relatively small) [17]. In the first
stage of the simulation we randomly partitioned the sam-
ples in this dataset into two equal subsets, A and B. We
then randomly selected unique subsets of genes and intro-
duced simulated Fold Changes (FC) in the B samples.
1000 genes were set with a FC of 1.5 up, 500 2 fold up,
300 4 fold up, 200 8 fold up; and then 200 were set down
1.5 fold, 200 down 2 fold, and 100 down 4 fold. This gives
a total of 2000 up regulated genes with FC in the range of
1.5 to 8 compared to only 500 down regulated genes with
FC in the range of -1.5 to -4 so that both the number and
degree of up and down regulation is heavily biased in the
up direction. In the second stage of the simulation we
added random non-linear skew to each sample. The third
and final stage of the simulation was to apply GRSN to
correct the skew just added. We have repeated this com-
plete simulation, starting with the random partitioning of
the original 10 control samples, 100 times (randomly
selecting 100 unique permutations from the 252 possible
permutations). Figure 4A shows M vs. A plots demonstrat-
ing typical skews introduced in a selected sample in two
of the 100 different simulations. This figure shows a
selected sample compared to the virtual reference sample
both before and after the introduction of a simulated
skew, and then shows the effect of applying GRSN to cor-
rect the simulated skew (compare these plots to Fig. 2).
At each stage of each simulation (after simulated FC is
introduced, after simulated skew is added, and after GRSN
is applied to correct the simulated skew), the Standard
Deviation (SD) within replicates and the average FC
between A and B sample subsets is calculated for each
gene. A goal of GRSN is to reduce the SD among repli-
cates. As shown in Table 1, the average SD among repli-BMC Bioinformatics 2008, 9:520 http://www.biomedcentral.com/1471-2105/9/520
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Simulation study showing the performance of GRSN Figure 4
Simulation study showing the performance of GRSN. Differential gene expression was simulated starting with a dataset 
containing 10 biological replicates. The simulation was repeated 100 times and each time the 10 samples were divided into two 
equal groups, gene expression was simulated in the second group, and a randomly generated, non-linear artifact (skew) was 
applied to each sample. In each simulation, GRSN was applied to correct the simulated skew. A. First row – sample 8 of 10 
from simulation 100 of 100. Left hand panel shows M vs. A plot before simulated skew. Second panel from left shows the intro-
duction of simulated skew. Third panel from left shows GRiS and calibration curve from GRSN process. Right hand panel 
shows data after GRSN correction of simulated skew. Second row – same as first row, but for simulation 81 of 100. B. GRSN 
improves gene selection results. Left panel shows true positive gene selection results for simulated up and down genes as indi-
cated before simulated skew is added, after simulated skew is added, and after GRSN is used to correct the simulated skew. 
Critical portions of the y-axis scale are expanded at the top and bottom of the graph. Middle panel shows false negatives with 
the bottom portion of the y-axis scale expanded at the bottom. Right panel shows false positive results. Data is represented 
using standard Tukey box plots. C. Average Fold Change (FC) variation. The average FC for each simulated FC value is plotted 
showing the variation over all simulated genes and 100 simulations. The left third of the graph shows values for simulated data 
before skew is introduced, the middle third shows values with skew added, and the right third shows values after GRSN cor-
rection of skew as indicated. Box plots are shown.
3
-2
-1
0
1
2
l
o
g
2
a
v
g
.
f
o
l
d
c
h
a
n
g
e
Average Fold ChangeV ariation C
FC: 1.5 4 8 2 1.5 4 2
Up Down
Simulated FC
1.5 4 8 2 1.5 4 2
Up Down
Simulated Skew
1.5 4 8 2 1.5 4 2
Up Down
GRSN Corrected
8 fold up
2 fold down
4 fold down
1.5 fold up
4 fold up
2 fold up
1.5 fold down
True Positives
2000
1000
500
1500
500
490
495
U
p
D
n
U
p
D
n
U
p
D
n
1990
1995
2000
2005
S
t
a
t
i
s
t
i
c
a
l
l
y
S
i
g
n
i
f
i
c
a
n
t
G
e
n
e
s
F
o
u
n
d
False Positives
10000
0
15
5000
10
0
5
U
p
D
n
U
p
D
n
U
p
D
n
15000
20000
S
t
a
t
i
s
t
i
c
a
l
l
y
S
i
g
n
i
f
i
c
a
n
t
G
e
n
e
s
F
o
u
n
d
20
False Negatives
1000
0
15
500
10
0
U
p
D
n
U
p
D
n
U
p
D
n
1500
S
t
a
t
i
s
t
i
c
a
l
l
y
S
i
g
n
i
f
i
c
a
n
t
G
e
n
e
s
F
o
u
n
d
20
5
B
GRSN Corrected
(log2(GFP8)+log2(Ref.))/2
l
o
g
2
(
G
F
P
8
)
-
l
o
g
2
(
R
e
f
.
) Simulation 100 of 100
Sample 8 of 10
4 6 8 1 01 21 4
-
2
-
1
0
1
Rank Invariant Set
l
o
g
2
(
G
F
P
8
)
-
l
o
g
2
(
R
e
f
.
) Simulation 100 of 100
Sample 8 of 10
468 1 0 1 2 1 4
-
1
.
0
-
0
.
5
0
.
0
0
.
5 Simulated Skew
l
o
g
2
(
G
F
P
8
)
-
l
o
g
2
(
R
e
f
.
) Simulation 100 of 100
Sample 8 of 10
4 6 8 1 01 21 4
-
2
.
0
-
1
.
0
0
.
0
1
.
0 RMAProcessed
(log2(GFP8)+log2(Ref.))/2
l
o
g
2
(
G
F
P
8
)
-
l
o
g
2
(
R
e
f
.
) Simulation 100 of 100
Sample 8 of 10
4 6 8 10 12 14
-
2
.
0
-
1
.
0
0
.
0
1
.
0
RMAProcessed
(log2(GFP8)+log2(Ref.))/2
l
o
g
2
(
G
F
P
8
)
-
l
o
g
2
(
R
e
f
.
) Simulation 81 of 100
Sample 8 of 10
4 6 8 10 12 14
-
2
.
0
-
1
.
0
0
.
0
1
.
0 Simulation 81 of 100
Sample 8 of 10
468 1 0 1 2 1 4
-
2
.
0
-
1
.
0
0
.
0
1
.
0
(log2(GFP8)+log2(Ref.))/2
l
o
g
2
(
G
F
P
8
)
-
l
o
g
2
(
R
e
f
.
)
GRSN Corrected
Simulation 81 of 100
Sample 8 of 10
468 1 0 1 2 1 4
-
1
.
5
-
1
.
0
-
0
.
5
0
.
0
(log2(GFP8)+log2(Ref.))/2
l
o
g
2
(
G
F
P
8
)
-
l
o
g
2
(
R
e
f
.
)
Rank Invariant Set
Simulation 81 of 100
Sample 8 of 10
468 1 0 1 2 1 4
-
2
.
0
-
1
.
0
0
.
0
1
.
0
(log2(GFP8)+log2(Ref.))/2
l
o
g
2
(
G
F
P
8
)
-
l
o
g
2
(
R
e
f
.
)
Simulated Skew
(log2(GFP8)+log2(Ref.))/2 (log2GFP8)+log2(Ref.))/2
A
Sim. Skew
GRSN Cor.
Sim. FC
Sim. Skew
GRSN Cor.
Sim. FC
Sim. Skew
GRSN Cor.
Sim. FCBMC Bioinformatics 2008, 9:520 http://www.biomedcentral.com/1471-2105/9/520
Page 9 of 18
(page number not for citation purposes)
cates is highest in the data with simulated skew and is
substantially reduced when GRSN correction is applied.
The SD after GRSN correction is almost identical to the SD
for the original data before simulated skew is introduced
(see Table 1). In addition to removing unwanted technical
variation, it is important to preserve biologically relevant
variation. In this simulation, the biologically relevant var-
iation is the simulated FC introduced in sample set B.
Here we calculate the average for all simulated FC ranges
up or down across all simulations. In our study, the aver-
age FC value stays relatively constant (within 2–3%) at
each stage of the simulation (see Table 1), demonstrating
that GRSN does not adversely affect the relevant variation
(also see Fig. 4C).
Next we evaluated the effects of the introduced skews and
GRSN correction on statistical gene selection performance
in our simulated datasets. Statistically significant genes
were selected with eBayes using a FC cutoff of 1.2 and a
FDR cutoff of 0.05. We evaluated the numbers of True
Positive (TP) (genes with actual simulated FC), False Pos-
itive (FP), and False Negative (FN) genes found at each
stage of the data simulation for each of the 100 simula-
tions run. Figure 4B shows the results using box plots
showing the range of gene selection results across all 100
simulations. The statistical results from the data with sim-
ulated artifacts, but no GRSN correction, vary widely from
simulation to simulation, resulting in a substantial reduc-
tion in identified true positives (middle data set in left
plot), and an abundance of false negatives and false posi-
tives (middle data sets in middle and right-hand plots).
False negatives are more common than false positives due
to the random nature of the introduced skew. However,
GRSN corrects these issues and the results both before the
simulated artifacts and after the simulated artifacts have
been corrected with GRSN are very stable (Fig. 4B, com-
pare left and right-hand data sets in each box plot).
We also evaluated the ability of GRSN to preserve the Fold
Change (FC) values introduced in the above simulation.
We tabulated the average FC for each range over all 100
simulations. This tabulation was done for each stage of
the simulation: after simulated FC, after simulated skew,
and after GRSN correction. Box plots were used to sum-
marize the results for each FC range and each stage. As
seen in Fig. 4C, the variation in FC for each simulated FC
range is increased substantially by the simulated skew, but
the application of GRSN restores both the mean FC and
the variation in FC to values very close to the pre-skew val-
ues.
GRSN corrects non-linear distortions in representative 
microarray datasets
We have investigated the application of GRSN on a wide
variety of microarray datasets including clinical sample
datasets, cell culture datasets with various treatment
modalities, and genetic mouse model datasets [18-21]
[see Additional file 1]. Two examples are shown in Figure
5A with RMA pre-processing. 1) A mouse model (MKM
dataset) of carcinogenesis in cultured clonal keratinocytes
[22,23]. Samples were run on the Affymetrix® MOE430A
GeneChip®. This dataset represents cell culture based
experiments with minimal biological variance between
replicate samples. 2) A study of limb development in a
mouse model (SS dataset) courtesy of Dr. Scott Stadler at
OHSU [24]. Samples were run on the Affymetrix®
MOE430A GeneChip®. This study compares mutant vs.
wild type mice with three female and three male replicates
for each condition. In both cases we see a reduction in the
systematic intensity-dependent artifacts observed in these
samples with application of GRSN (Fig. 5A, right-hand
column).
When datasets are analyzed for Fold Change between two
experimental conditions where each gene's average FC
between conditions is plotted versus its average expres-
sion for both conditions on M vs. A plots, we also often
see non-linear skewing in the data even after averaging
replicate samples and regardless of the pre-processing
method. This is again likely resulting from the systematic,
Table 1: GRSN reduces standard deviation while preserving introduced fold change in a simulated data study.
Stage of data simulation Avg. SD of replicates Avg. abs FC, samples B vs. A
All Genes Up & Dn Genes Up Genes Dn Genes
Sim. FC 15.24 24.37 2.67 -1.92
Sim. Skew 35.49 52.55 2.72 -1.90
GRSN correction 14.68 24.97 2.66 -1.92
Average Standard Deviation (SD) among replicates and average Fold Change (FC) are reported for each stage of our simulated data study (see text 
for description). SD values for each gene are calculated separately for sample set A and sample set B and then averaged across both sample sets and 
all 100 simulations. FC values are calculated for each gene by taking the average for sample set B and dividing by the average for sample set A then 
averaging over all 100 simulations. The values reported in each column are (from left to right) 1) the average SD for all genes, 2) the average SD for 
the up and down regulated genes, 3) the average FC for up regulated genes, and 4) the average FC for down regulated genes. Values reported in the 
top row are for data with simulated FC only. Values in the middle row are for data with simulated skew added. The bottom row reports values 
after GRSN correction of the simulated skew.BMC Bioinformatics 2008, 9:520 http://www.biomedcentral.com/1471-2105/9/520
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intensity-dependent artifacts which have no biological
significance and it appears at least in some cases to be
exacerbated in datasets containing unbalanced numbers
of up or down regulated genes. For example, Fig. 5B shows
M vs. A plots of the GB dataset comparing 14 Fanconi
Anemia samples to 11 normal bone marrow samples
before and after applying GRSN. In this example, non-lin-
ear distortions are seen without GRSN correction when
MAS 5.0 pre-processing is used (top row, left panel), as
well as when RMA pre-processing (middle row, left
panel), and dChip pre-processing (bottom row, left
panel) are used. However, applying GRSN substantially
reduces this skew in all cases (Fig. 5B, right-hand panels).
Thus, in some datasets, FC assessments can be affected by
non-linear artifacts even when averaging multiple, repli-
cate samples and regardless of the probe set summary
method used. For each summary method shown, GRSN
effectively reduces this skew. The same results are seen
with additional datasets [see Additional file 2].
Reduction of systematic variation by GRSN
The goal of GRSN is to reduce systematic non-linear vari-
ation in microarray datasets. GRSN is very successful at
this task as demonstrated with simulated data. However,
there is also random variation in any microarray dataset
and this random variation tends to be larger than the sys-
tematic variation addressed by GRSN. As a result, applying
GRSN will not reduce the variation of all genes and the
variation of some genes will actually increase due to the
random nature of the non-systematic variation. Still, in
most cases, GRSN will reduce the average variation among
replicates as shown in Fig. 6. The main benefit seen from
this reduction in average variance is in the genes with rel-
atively small random and biological variations. These
genes are at the largest risk of becoming false positives due
to systematic non-linear artifacts. An example of this is
seen in the SS dataset (Fig. 7C).
Implications of GRSN for gene discovery
An important goal of many microarray-based studies is
the identification of genes with statistically significant dif-
ferential expression between experimental conditions. As
seen with the simulated data study and as shown in real
data sets in Fig. 5B, the non-linear skew seen in some data-
sets is likely to significantly impact standard statistical
methods for selecting differentially regulated genes. To
analyze this we compared statistical results before and
after applying GRSN normalization to a number of data-
sets. We selected significant up and down regulated tran-
scripts that pass a Fold Change threshold of 1.5 and a
False Discovery Rate threshold of 0.05 (similar results are
obtained using FDR values ranging from 0.01 to 0.20). In
Fig. 7A, we use the same M vs. A plots as in Fig. 5B, but add
color coding to visualize genes selected as statistically up
or down regulated between two sample classes. The "S"
shaped skew in the data effects both the calculation of sta-
tistical significance and the calculation of fold change. In
Fig. 7A, genes from the GB dataset summarized with RMA
are color coded based on meeting both a statistical and a
fold change cutoff. Transcripts found significant only
when GRSN is not applied are indicated in blue, tran-
scripts found significant only when GRSN is applied are
indicated in red, and transcripts found significant in both
cases are indicated in yellow. The blue horizontal lines
indicate the FC threshold applied to select the blue tran-
scripts (left panel) and the red horizontal lines indicate
the FC threshold applied to select the red transcripts (right
panel). In this case, it can be seen that the skew is pushing
large groups of genes in or out of the selected fold change
range. In Fig. 7B–D the color coding is modified to show
the blue genes only on the left and red genes only on the
right and in Fig. 7B there are more blue genes lost with the
application of GRSN than there are red genes gained. This
result is misleading, because the median p-value for the
yellow genes (genes found in both cases) has decreased
(improved) from 0.00023 to 0.00021 with the applica-
tion of GRSN. The reason less genes are found after apply-
ing GRSN is due to the FDR adjustment. The p-value
required to meet the 0.05 FDR threshold before applica-
tion of GRSN was 0.0015 while the required p-value after
GRSN application was 0.0010. Therefore, the p-value
threshold associated with the given FDR value became
more stringent after applying GRSN. This is most likely
due to the distribution of p-values for genes that did not
make the FC cutoff. The cause of this is well illustrated in
Fig. 7C with the SS dataset. Here, statistics alone, with the
FDR threshold reduced to 0.10 and with no fold change
cutoff, are used to select genes. In this case, it appears that
there are large groups of genes that are detected as statisti-
cally significant due solely to the effect of the "S" shaped
skew in the data. In fact, applying GRSN in this case
reduces the total number of genes selected from approxi-
mately 1,800 to only 171 genes significantly up regulated
and 295 genes significantly down regulated (1,344 signif-
icant genes were removed and only 20 added). These large
numbers of false positive results will cause overly optimis-
tic FDR calculations for all genes and removing these false
positive results with the use of GRSN results in fewer
genes passing the FDR cutoff even when the actual p-val-
ues have improved. In Fig. 7D there are a significant
number of red genes added when GRSN is applied and no
blue genes lost. In this case, the median p-value for the
yellow genes improved significantly from 0.000076 to
0.000042 while the p-value required to meet the FDR
threshold changed from 0.00020 to 0.00070. In this case,
the FDR threshold became less stringent with the applica-
tion of GRSN. Presumably the benefit from a decrease in
variance among replicates out weighed any bias in the
FDR calculation introduced by the removal of false posi-
tives (no false positive are shown because they areBMC Bioinformatics 2008, 9:520 http://www.biomedcentral.com/1471-2105/9/520
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GRSN corrects non-linear artifacts in representative microarray datasets Figure 5
GRSN corrects non-linear artifacts in representative microarray datasets. A. GRSN applied to two different micro-
array datasets. First row – late stage sample L3 from the MKM dataset. Second row – mutant Male sample MutM2 from the SS 
dataset. Columns 1–3 demonstrate the effect of GRSN on the selected samples as described in figure 2 above. The RMA probe 
set summary method was used in each. B. GRSN can reduce systematic non-linear artifacts which can affect fold change analy-
sis regardless of pre-processing method. M vs. A plots showing fold change as a function of mean value and plotted on log base 
2 scale. Both fold change and mean are calculated using multiple replicates, 14 FA samples and 11 Normal samples from the GB 
dataset (not just comparing two samples). A lowess smoothed curve is displayed to show the trend of the scatter plots. Three 
different summary methods are shown: Top row – MAS 5.0, Middle row – RMA, and Bottom row – dChip®. The results in the 
left column are without GRSN applied and the effect of applying GRSN to each of the respective methods is shown in the right 
column.
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"masked" by the FC threshold). In summary, systematic
distortions in microarray datasets are likely to adversely
impact statistical calculations leading to unreliable gene
selection results.
GRSN improves downstream pathway analysis using Gene 
Set Enrichment Analysis (GSEA)
In addition to examining the effects of GRSN on variance
and statistical gene selection we have used the GSEA tool
[25] to further analyze the effects of GRSN on down-
stream microarray data analysis. GSEA looks for the
enrichment of known pathways (sets of genes) in the
"gene signature" of a particular experiment. Part of the
power of GSEA is that it considers the rank and signifi-
cance of all genes in the gene signature. Therefore, GSEA
will benefit both from an increase in True Positives and in
a decrease in False Positive gene selection results with the
use of GRSN. We have applied GSEA to both the RS and
the SS datasets (using the 'R' implementation, version
GSEA.1.0.R). The ability of GSEA to detect pathways
shown to be relevant in each of these datasets is evaluated
both with and without the use of GRSN. As shown in
Table 2, both the Normalized Enrichment Score (NES)
and the False Discovery Rate (FDR) for these relevant
pathways are consistently improved and in some cases,
pathways are only detected when GRSN is used. In partic-
ular, VEGF is identified as an important player in the SS
study [24] but the associated "vegfPathway" is only iden-
tified by GSEA when the data is normalized with GRSN.
Also, the RS study involves expression of the c-Myc onco-
protein, which is known to induce cell cycle, cell prolifer-
ation, cell growth, DNA damage, cell death, and HTERT
(see references in Table 2). GSEA identifies all of these
pathways to be enriched with c-Myc expression compared
to control and as shown in Table 2 all of these pathways
GRSN reduces average variance in datasets Figure 6
GRSN reduces average variance in datasets. Lowess curves are plotted summarizing the variance (for log base 2 scaled 
data) of all genes among selected sets of replicate samples and whole datasets. The curves show the trend in the variance as a 
function of expression values. Dashed blue is RMA processed data and dashed red is RMA processed data with GRSN post 
processing. A. RS dataset showing variance reduction in Control samples, Myc samples, and control and Myc samples com-
bined. B. SS dataset showing, WT samples, mutant samples, and WT and mutant samples combined.
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GRSN impacts gene discovery Figure 7
GRSN impacts gene discovery. Averaged fold change M vs. A plots as in Figure 5B, but with color coding added to show 
genes passing fold change and statistical thresholds for significant differential regulation between experimental conditions. Sta-
tistical thresholds reported in this figure are for FDR adjusted p-values from standard t-tests. A) GB data comparing 14 Fanconi 
Anemia samples to 11 Normal samples and plotted using values from RMA method alone (left panel) and using values from 
RMA with GRSN (right panel). Both plots are color coded to show genes found to be significantly changed (FC of at least 1.5 
and FDR of no more than 0.05): genes found only when using RMA alone are in blue, genes found only when using RMA with 
GRSN are in red, and genes found in both cases are in yellow. The horizontal colored lines show the fold change cutoff applied 
to the respective summary and normalization methods. B-C) Color coding is modified so that blue genes are shown only in the 
left panel and red genes are shown only in the right panel. B) GSE6475 data comparing 6 AL (acne lesion) replicates to 6 AN 
(acne normal) replicates. Samples are plotted as in A. C) SS data comparing 6 mutant samples to 6 wild type (3 male and 3 
female for each condition). No FC threshold is applied in this example and the FDR threshold is set to 0.10. D) GSE7664 data 
comparing 8 bt (treated) to 8 med (untreated) samples plotted as in A.
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are detected at a higher NES and much more significant
FDR value when GRSN is used.
Discussion
With any data manipulation there is a risk of adding
noise. This is a classic problem with background subtrac-
tion where subtracting one noisy signal from another
noisy signal can actually double the noise. The goal of
GRSN is to remove intensity-dependent, technical varia-
tion in the data, but we need to make sure that we do not
increase the random noise at the same time. GRSN mini-
mizes this risk in a number of ways. First, by using a global
rank-invariant set, we ensure that any noise associated
with the selection of the rank-invariant set is applied
equally to all samples. This both reduces the risk of adding
random variance among replicate samples and reduces
the risk of adding bias between sample groups. Second,
the iterative method used to select the rank-invariant set
ensures that the set is not biased by unbalanced numbers
of up or down regulated genes or by unequal degrees of up
or down regulation. Third, a single robust virtual reference
sample is generated by taking the trimmed mean value
(among all samples) of each gene in the global rank-invar-
iant set. This ensures that the linearity of the normalized
data is not affected by a few abnormal samples, but is a
robust reflection of the dataset as a whole. Forth, the
actual intensity-dependent calibration applied to each
sample is calculated using a robust lowess smoothing
algorithm through many points. Therefore, each sample is
compared to the same "representative" virtual reference
and the actual calibration is calculated using a rigorous
averaging of many reference and comparison data points.
An important distinction between GRSN and other nor-
malization methods is simply when it is applied. We are
applying it to the probe set level data after it has been
processed and summarized by other methods. This has
the advantage that the expression value for a given tran-
script should more accurately reflect its actual value than
will the individual probe values. Other authors have also
advocated the application of additional normalization at
the probe set level [10]. While we have not investigated
applying GRSN to probe level data, we have tried applying
the RMA type of quantile normalization to probe set level
data. Interestingly, compared to the standard method of
applying quantile normalization at the probe level, this
yields results more similar to GRSN. We have also investi-
gated substituting lowess normalization for the quantile
normalization step in the RMA method (at the probe
level) and found it to lead to increased non-linear skew.
When GRSN is applied, this increased skew is significantly
reduced (data not shown). This suggests that the quantile
normalization step is not the cause of the skew and nei-
ther is a simple substitution of lowess the solution to the
skew.
It is important to note that the typical degree of skewing
seen in datasets processed with the RMA method is rela-
tively small in terms of absolute fold change. Therefore, a
typical fold change cutoff threshold of 1.5 or 2.0 will mask
most of this effect and avoid most false positives. For
example, if a fold change cutoff of 2.0 is applied to the
data shown in Fig. 7C, all but one of the false positive
results reported will be masked, although this is not true
for the data in Fig. 7A. However, even when the false pos-
itives are masked, they are still affecting the False Discov-
ery Rate calculation for all genes, leading to overly
optimistic values. This is probably more of a problem
than the errors in the fold change values for the selected
genes.
Conclusion
When microarray data from the Affymetrix® platform is
processed using the MAS 5.0 algorithm (still a common
practice), it is crucial to check for non-linear artifacts. A
simple way to do this is to look at log scale scatter plots
comparing pairs of samples. If the trend for any of the
scatter plots deviates from the diagonal, additional steps
should be taken to normalize the data [10]. The global,
rank-invariant set based method (GRSN) presented here is
a robust method to address this need. A less obvious and
more profound finding is that even when using methods
such as RMA or dChip® (with more sophisticated normal-
ization methods built in), it is still important to check for
non-linear artifacts. In particular, datasets with unbal-
anced numbers of up and down regulated genes often
have an expression level dependent skew when compar-
ing conditions. GRSN is able to correct this skew without
introducing bias. In other words, GRSN does not try to
balance up and down gene expression. This skew is not
always obvious on a standard log scale scatter plot but can
be seen on an M vs. A plot and can adversely impact the
calculation of fold change and statistical significance and
in some cases can lead to false negative and/or false posi-
tive results. Using simulated data where we controlled
gene expression and non-linear skew, we have demon-
strated how this type of skew can lead to both false nega-
tive and false positive gene selection results, and we have
shown that GRSN can effectively reduce these artifacts,
resulting in much more accurate gene selection perform-
ance similar to what was obtained when no skew was
present. We also show that GRSN correction of the intro-
duced skew reduces standard deviation among replicates
while preserving the magnitude of introduced fold-
change. Moreover, we have shown that application of
GRSN to real datasets reduces variance among replicatesBMC Bioinformatics 2008, 9:520 http://www.biomedcentral.com/1471-2105/9/520
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and improves gene pathway enrichment scores for known
pathways in datasets.
In summary, GRSN is a robust post-processing normaliza-
tion step that can correct non-linear systematic distortions
in microarray datasets resulting in improved statistical
performance, more accurate gene discovery, and
enhanced pathway enrichment analysis. GRSN is freely
available for non-commercial use [see Availability and
requirements section]. This report focuses on data from
the Affymetrix® platform, but GRSN should apply equally
well to high-density data from other microarray plat-
forms.
Availability and requirements
This tool is available for free for non-commercial use [see
Additional file 3]. Any commercial use requires prior writ-
ten permission from the author and Oregon Health and
Science University and may require licensing fees. An
implementation based on the "R" statistical computing
language is provided with source code included. The
scripts have been developed and tested using Windows
XP®, but should work on other operating systems which
are supported by the "R" statistical platform, including
MacOS and Linux. Multiple "R" versions have been tested,
including version 2.4.0. Future updates and additional
information will be provided at: Sears Lab when available.
Methods
Software
All statistical analysis, method implementation, and
graphing for figures, was performed using the open-source
programming language R, Versions 2.0.1 – 2.4.0 [26], and
Bioconductor packages http://www.bioconductor.org.
Affymetrix® CEL files were processed using the MAS 5.0
and RMA algorithms implemented in the BioConductor
package: affy Version 1.5.8 [27] (based on the R program-
ming language) and by dChip® 2006 (Build date: Feb. 16,
2006). Gene Set Enrichment Analysis (GSEA) was per-
formed using the author's R language implementation
version GSEA.1.0.R [25].
GRSN Implementation
At the heart of the GRSN method is the selection of a glo-
bal rank-invariant set. Microarray data is passed to GRSN
as a matrix of expression values with rows representing
transcripts (probe sets) and columns representing sam-
ples. The Affymetrix® control transcripts are excluded. Non
log scaled data is expected. If necessary, a fixed value is
added to all matrix entries to ensure that no entry is less
than 0.25. This is to ensure that when the data is log base
2 (log2) scaled, no values will be less than negative 2.0.
The data is then log2 scaled. Next, a rank matrix of the
same dimension as the input matrix is calculated. For each
column of the input matrix, the rank (order in a sorted
Table 2: GRSN aids Gene Set Enrichment Analysis (GSEA).
SS dataset (mutant vs. control) Without GRSN With GRSN
Pathway NES FDR NES FDR
CR_CYTOSKELETON [28,29] 0.9053 0.6021 1.2209 0.2131
vegfPathway [24] Not found 1.1346 0.2775
cell_adhesion [30] Not found 0.9004 0.6332
RS dataset (Myc vs. control) Without GRSN With GRSN
Pathway NES FDR NES FDR
Cell_Cycle [31] 1.6516 0.1171 1.7633 0.0240
CR_CELL_CYCLE [31] 1.5565 0.1221 1.6751 0.0488
G1_CELL_CYCLE [31] 1.6902 0.1461 1.6913 0.0398
DNA_DAMAGE_SIGNALLING [32] 1.5355 0.1353 1.6632 0.0490
cell_proliferation [31] 1.6101 0.1161 1.6207 0.0884
cell_cycle_checkpoint [31] 1.4528 0.1941 1.5852 0.1192
PROLIF_GENES [31] 1.5104 0.1539 1.5745 0.1139
cell_growth_and_or_maintenance [33] 1.4340 0.1984 1.5681 0.1099
HTERT_UP [33] 1.4436 0.2064 1.5566 0.1066
cellcyclePathway [31] 1.4618 0.1887 1.4981 0.1357
CR_DEATH [34] 0.9966 0.5629 1.2257 0.3680
GSEA is applied to the SS and RS datasets. Pathways known to be active in these datasets are shown and referenced. For each selected pathway, the 
Normalized Enrichment Score (NES) and the False Discovery Rate (FDR), as reported by GSEA, are shown. NES and FDR values are shown both 
for data processed with RMA alone (Without GRSN) and for data processed with RMA followed by GRSN (With GRSN) as indicated.BMC Bioinformatics 2008, 9:520 http://www.biomedcentral.com/1471-2105/9/520
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list) of each transcript in that column is calculated and
used to populate the rank matrix. The variance of each row
of the rank matrix is calculated and the rows are then
ranked based on their variance. The rows with the highest
variance are discarded. A subset of the original log2 scaled
matrix is produced, containing only the rows correspond-
ing to the remaining rows in the rank matrix. Using this
new matrix, another rank matrix is calculated. This proc-
ess is repeated in an iterative manner four (4) times. (The
number of rows to discard per iteration is calculated by
subtracting the selected size (default is 5000) for the Glo-
bal Rank-invariant Set (GRiS) from the original row count
and dividing the result by four.) The remaining transcripts
are considered the GRiS. Next, reference values for each of
the transcripts in the GRiS are obtained by calculating the
trimmed mean from all samples for each of the respective
transcripts. A calibration curve is then calculated for each
sample by comparing the GRiS values from the given sam-
ple to the GRiS reference values using an M vs. A plot. The
plotted points representing the GRiS should be centered
about the horizontal line where M = 0. The calibration
curve is obtained by drawing a smoothed line through
these points using lowess [13] as implemented in R (the
default smoother span used with GSRN is 0.25, but this
value may be adjusted if needed). The vertical displace-
ment between the smoothed calibration curve and the
horizontal line (M = 0) is used as an intensity dependant
adjustment to be applied to all transcripts in the given
sample. This adjustment is subtracted from the log2
scaled data (this is equivalent to applying an intensity
dependant scaling factor to non log scaled data). It should
be noted that the lowess smoothing and the calculation of
the intensity dependant adjustment values are done on
the data after it has been transformed for the M vs. A plot.
After the intensity dependant adjustment is applied, the M
vs. A transformation is reversed. Our implementation of
GRSN as an "R" script with directions is available [see
Additional file 3].
GRSN Graphical Visualization
Quality control graphs are plotted for each sample as it is
normalized. For each sample, three M vs. A scatter plots
are generated: The first is pre GRSN, and compares the
given sample to the virtual reference sample (a pseudo
sample with each transcript set to the trimmed mean
value for that transcript from all samples in a dataset). The
second shows the GRiS transcripts only, both before and
after adjustment, and includes the lowess smoothed cali-
bration curve. The third shows the given sample, after
adjustment, compared to the virtual reference sample.
Data simulation study
GRSN was evaluated using simulated data produced by
adding simulated gene expression and simulated non-lin-
ear artifacts (skew) to a cell culture dataset containing 10
replicated controls [14]. The 10 samples were first proc-
essed using the RMA method. Next, all possible permuta-
tions for dividing these 10 replicate samples into two
groups of 5 (set A and set B) were calculated. Out of the
252 possible permutations, we randomly selected 100,
thus ensuring that we had 100 randomly selected, yet dis-
tinct partitions of the original data. For each of these 100
distinct partitions (hereafter called a simulation), we
added simulated Fold Change (FC) by applying a multi-
plication factor to selected transcripts (genes) in all sam-
ples in set B. For each simulation, we randomly selected
2500 genes. The first 1000 (out of the 2500 selected) were
multiplied by +1.5 to simulate a FC of 1.5 up. A factor of
+2 was applied to the next 500, a factor of +4 to the next
300, a factor of +8 to the next 200, a factor of 2/3 to the
next 200, a factor of 1/2 to the next 200, and a factor of 1/
4 to the final 100 genes. Thus, up regulation with FC in
the range of 1.5 to 8 was simulated for 2000 genes and
down regulation with FC in the range of -1.5 to -4 was
simulated in 500 genes. The next step in each simulation
was to add distinct, randomly generated skew to each
sample. This was done by randomly generating curves
similar to the calibration curves produced by GRSN when
normalizing RMA processed data and using these as "cal-
ibration curves" to add intensity-dependent skew to the
simulated samples. The final step in each simulation was
to apply GRSN to correct the introduced skew. The simu-
lated data was analyzed at each of the three stages in the
simulation process just described, 1) after simulated FC
was introduced, 2) after simulated skew was added, and
3) after GRSN was applied to correct the simulated skew.
The results of these analyses were tabulated and/or aver-
aged over all 100 simulations and reported in the results
section.
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